| 期刊論文| 1. | Zhang, Q. L.、Rothenbacher, D.(2008)。Prevalence of chronic kidney disease in population-based studies: Systematic review。BMC Public Health，8(1)，117。   | | 2. | Jha, V.、Garcia-Garcia, G.、Iseki, K.、Li, Z.、Naicker, S.、Plattner, B.、Saran, R.、Wang, A. Y.、Yang, C. W.(2013)。Chronic kidney disease: Global dimension and perspectives。The Lancet，382(9888)，260-272。 | | 3. | Wen, C. P.、Cheng, T. Y. D.、Tsai, M. K.、Chen, Y. C.、Chan, H. T.、Tsai, S. P.、Wen, S. F.(2008)。All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462293 adults in Taiwan。Lancet，371(9631)，2173-2182。 | | 4. | Luo, J. C.、Leu, H. B.、Hou, M. C.(2013)。Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients。Am. J. Med.，126(3)，(264)e225-(264)e232。 | | 5. | 曲宏達、佟麗、沈劍剛、陳育堯(2002)。補陽還五湯對體外培養的大鼠皮層神經元缺氧凋亡的影響。第一軍醫大學學報，22，35-38。 延伸查詢 | | 6. | 趙雅寧、吳曉光、李建民、陳長香、饒穎臻、李淑杏(2010)。中藥補陽還五湯對沙鼠腦缺血再灌注損傷及微循環障礙的治療作用。四川大學學報（醫學版），41，53-56。 延伸查詢 | | 7. | 廖春來、佟麗、陳育堯(2004)。補陽還五湯對腦缺血大鼠nNOS免疫陽性神經元的影響。第一軍醫大學學報，24，864-868。 延伸查詢 | | 8. | 陳潔、曾耀英、曾慧蘭、陳孝銀、蘇澤軒、劉嘉雯、王喬峰、李偉、吳文燕(2009)。補陽還五湯預先乾預對大鼠腦死亡後腎臟炎症細胞因子表達的影響。中藥材，32，1855-1860。 延伸查詢 | | 9. | Lai, M. N.、Lai, J. N.、Chen, P. C.、Tseng, W. L.、Chen, Y. Y.、Hwang, J. S.、Wang, J. D.(2009)。Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid。Nephrology (Carlton)，14，227-234。 | | 10. | Kidney Disease Improving Global Outcomes CKD Work Group(2013)。KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease。Kidney Int. Suppl.，3，1-150。 | | 11. | Strippoli, G. F.、Bonifati, C.、Craig, M.、Navaneethan, S. D.、Craig, J. C.(2006)。Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease。Cochrane Database Syst Rev.，4，CD006257。 | | 12. | Doulton, T. W.、He, F. J.、MacGregor, G. A.(2005)。Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension。Hypertension，45(5)，880-886。 | | 13. | MacKinnon, M.、Shurraw, S.、Akbari, A.、Knoll, G. A.、Jaffey, J.、Clark, H. D.(2006)。Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data。Am J Kidney Dis，48(1)，8-20。 | | 14. | Hsu, P. C.、Tsai, Y. T.、Lai, J. N.、Wu, C. T.、Lin, S. K.、Huang, C. Y.(2014)。Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study。J. Ethnopharmacol，156，358-364。 | | 15. | Lin, M. Y.、Chiu, Y. W.、Chang, J. S.、Lin, H. L.、Lee, C. T.、Chiu, G. F.、Kuo, M. C.、Wu, M. T.、Chen, H. C.、Hwang, S. J.(2015)。Association of prescribed Chinese herbal medicine use with risk of end-Stage renal disease in patients with chronic kidney disease。Kidney Int.，88(6)，1365-1373。 | | 16. | 楊宗憲、陳星諭、楊賢鴻、林意旋、方基存、洪振傑、陳俊良(20140600)。Utilization Pattern for Traditional Chinese Medicine among Late Stage Chronic Kidney Disease Patients: A Hospital-Based Cross-sectional Study。中醫藥雜誌，25(1)，41-58。 延伸查詢 | | 17. | Hsieh, C. F.、Huang, S. L.、Chen, C. L.、Chen, W. T.、Chang, H. C.、Yang, C. C.(2014)。Non-aristolochic acid prescribed Chinese herbal medicines and the risk of mortality in patients with chronic kidney disease: results from a population-based follow-up study。BMJ Open，4(2)。 | | 18. | Wang, S. M.、Lai, M. N.、Wei, A.、Chen, Y. Y.、Pu, Y. S.、Chen, P. C.、Wang, J. D.(2014)。Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid。PLoS One，9(8)，e105218。 | | 19. | Su, T.、Mao, C.、Yin, F.、Yu, Z.、Lin, Y.、Song, Y.、Lu, T.(2013)。Effects of unprocessed versus vinegar-processed Schisandrachinensison the activity and mRNA expression of CYP1A2, CYP2E1 and CYP3A4 enzymes in rats。J. Ethnopharmacol，146(3)，734-743。 | | 20. | Saruwatari, J.、Takashima, A.、Yoshida, K.、Soraoka, H.、Ding, T. B.、Uchiyashiki, Y.、Tsuda, Y.、Imamura, M.、Oniki, K.、Miyata, K.、Nakagawa, K.(2014)。Effects of Seijo-bofu-to, a Traditional Japanese Herbal Medicine Containing Furanocoumarin Derivatives, on the Drug-Metabolizing Enzyme Activities in Healthy Male Volunteers。Basic Clin Pharmacol Toxicol，115(4)，360-365。 | | 21. | Li, X.、Hu, J.、Wang, B.、Sheng, L.、Liu, Z.、Yang, S.、Li, Y.(2014)。Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: Herb-drug interactions mediated via P-gp。Toxicol Appl Pharmacol，275(2)，163-175。 | | 22. | Park, H. J.、Shim, H. S.、Chung, S. Y.、Lee, T. H.、Shim, I.(2014)。Soyo-san reduces depressive-like behavior and proinflammatory cytokines in ovariectomized female rats。BMC Complement Altern Med，14。 | | 23. | Liu, C. X.、Yi, X. L.、Si, D. Y.、Xiao, X. F.、He, X.、Li, Y. Z.(2011)。Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters。Curr Drug Metab，12(9)，835-849。 | | 24. | Hou, M. L.、Lu, C. M.、Tsai, T. H.(2016)。Effects of Jia-Wei-Xiao-Yao-San on the Peripheral and Lymphatic Pharmacokinetics of Paclitaxel in Rats。Evid Based Complement Alternat Med，2016，5614747。 | | 25. | Chiang, M. H.、Chang, L. W.、Wang, J. W.、Lin, L. C.、Tsai, T. H.(2015)。Herb-Drug Pharmacokinetic Interaction of a Traditional Chinese Medicine Jia-Wei-Xiao-Yao-San with 5-Fluorouracil in the Blood and Brain of Rat Using Microdialysis。Evid Based Complement Alternat Med，2015，729679。 | | 26. | Nagler, E. V.、Webster, A. C.、Vanholder, R.、Zoccali, C.(2012)。Antidepressants for depression in Stage 3-5chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice(ERBP)。Nephrol. Dial. Transplant.，27(10)，3736-3745。 | | 27. | Hedayati, S. S.、Finkelstein, F. O.(2009)。Epidemiology, Diagnosis, and Management of Depression in Patients With CKD。Am. J. Kidney Dis.，54(4)，741-752。 | | 28. | Chen, Y. L.、Lee, C. Y.、Huang, K. H.、Kuan, Y. H.、Chen, M.. H.、Kuan, Y. H.、Chen, M.(2015)。Prescription patterns of Chinese herbal products for patients with sleep disorder and major depressive disorder in Taiwan。J. Ethnopharmacol，171，307-316。 | | 29. | Cui, H. J.、Yang, A. L.、Zhou, H. J.、Wang, C.、Luo, J. K.、Lin, Y.、Zong, Y. X.、Tang, T.(2015)。Buyang huanwu decoction promotes angiogenesis via vascular endothelial growth factor receptor-2 activation through the PI3K/Akt pathway in a mouse model of intracerebral hemorrhage。BMC Complement Altern Med，15。 | | 30. | Zhou, Y. C.、Liu, B.、Li, Y. J.、Jing, L. L.、Wen, G.、Tang, J.、Xu, X.、Lv, Z. P.、Sun, X. G.(2012)。Effects of Buyang Huanwu Decoction on Ventricular Remodeling and Differential Protein Profile in a Rat Model of Myocardial Infarction。Evid Based Complement Alternat Med，2012，385247。 | | 31. | Li, M.、Wang, W.、Xue, J.、Gu, Y.、Lin, S.(2011)。Meta-analysis of the clinical value of Astragalusmembranaceusin diabetic nephropathy。J. Ethnopharmacol，133(2)，412-419。 | | 32. | Shahzad, M.、Shabbir, A.、Wojcikowski, K.、Wohlmuth, H.、Gobe, G. C.(2016)。The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease。Curr Drug Targets，17(12)，1331-1340。 | | 33. | Zhang, H. W.、Lin, Z. X.、Xu, C.、Leung, C.、Chan, L. S.(2014)。Astragalus (a traditional Chinese medicine) for treating chronic kidney disease。Cochrane Database Syst Rev，10，CD008369。 | | 34. | Ma, Y. C.、Lin, C. C.、Li, C. I.、Chiang, J. H.、Li, T. C.、Lin, J. G.(2016)。Traditional Chinese medicine therapy improves the survival of systemic lupus erythematosus patients。Semin Arthritis Rheum，45(5)，596-603。 | | 35. | Ahmed, D.、Kumar, V.、Verma, A.、Shukla, G. S.、Sharma, M.(2015)。Antidiabetic, antioxidant, antihyperlipidemic effect of extract of Euryale ferox salisb. with enhanced histopathology of pancreas, liver and kidney in streptozotocin induced diabetic rats。Springerplus，4。 | | 36. | Wu, C. Y.、Wang, H.、He, X. X.、Wu, D. W.、Yue, W.、Wu, Q. N.(2017)。The hypoglycemic and antioxidant effects of polysaccharides from the petioles and pedicels of Euryale ferox Salisb. on alloxan-induced hyperglycemic mice。Food Funct，8(10)，3803-3813。 | | 37. | Ma, Z. G.、Xia, H. Q.、Cui, S. L.、Yu, J.(2017)。Attenuation of renal ischemic reperfusion injury by salvianolic acid B via suppressing oxidative stress and inflammation through PI3K/Akt signaling pathway。Braz J Med Biol Res，50(6)，e5954。 | | 38. | Liang, R.、Zhao, Q.、Jian, G.、Cheng, D.、Wang, N.、Zhang, G.、Wang, F.(2018)。Tanshinone II A Attenuates Contrast Induced Nephropathy via Nrf2 Activation in Rats。Cell Physiol Biochem，46(6)，2616-2623。 | | 39. | 胡穎、林斐莉、鄒慶玲、牟利軍(2013)。薏苡仁油對UUO大鼠腎間質纖維化的影響。中國中藥雜誌，38(12)，1982-1986。 延伸查詢 | | 40. | Chang, M. S.、Oh, M. S.、Kim, D. R.、Jung, K. J.、Park, S.、Choi, S. B.、Ko, B. S.、Park, S. K.(2006)。Effects of okchun-san, a herbal formulation, on blood glucose levels and body weight in a model of Type 2 diabetes。J. Ethnopharmacol，103(3)，491-495。 | | 41. | Li, B.、Qiao, L.、Li, L.、Zhang, Y.、Li, K.、Wang, L.、Qiao, Y. A.(2017)。Novel Antihypertensive Derived from Adlay (Coix larchryma-jobi L. var. ma-yuen Stapf) Glutelin。Molecules，22(1)。 | | 42. | Gao, Q. T.、Cheung, J. K.、Li, J.、Chu, G. K.、Duan, R.、Cheung, A. W.、Zhao, K. J.、Dong, T. T.、Tsim, K. W.(2006)。A Chinese herbal decoction, Danggui Buxue Tang, prepared from Radix Astragali and Radix Angelicae Sinensis stimulates the immune responses。Planta Med，72(13)，1227-1231。 | | 43. | 王立媛、王億平(2011)。慢性腎炎中醫藥研究近況。中醫藥臨床雜誌，23，652-653。 延伸查詢 | | 44. | 王劍飛、王耀獻、何萍、于瀚、劉玉寧、崔瑾(2017)。慢性腎小球腎炎本虛與標實証候分布及組合特點研究。現代中醫臨床，24，25-28。 延伸查詢 | | 45. | 劉尚建、劉玉甯、沈存、柳紅芳、孫魯英、王世東、孫衛衛、劉忠傑、王耀獻(2015)。腎絡癥瘕聚散理論的三態四期初探。中國中西醫結合腎病雜誌，16，350-351。 延伸查詢 | | 46. | 高菁、李靖、秦英、王蕾、張宏、李小翠、劉寶珠、來于、高菲菲(2013)。益腎補虛化瘀散結法治療慢性腎小球腎炎60例臨床研究總結。首都醫藥，2013(6)，47-50。 延伸查詢 | | 47. | 陳曾基、周麗芳、黃信彰(2003)。Application of a Data-mining Technique to Analyze Coprescription Patterns for Antacids in Taiwan。Clinical Therapeutics，25(9)，2453-2463。 | 學位論文| 1. | 申曉光(2009)。補陽還五湯對實驗性糖尿病大鼠腎臟ICAM, VCAM-1表達的影響(碩士論文)。河北醫科大學。 延伸查詢 | 圖書| 1. | Kasper, L. D.、Fauci, A. S.、Hauser, S.、Longo, D.、Jameson, J.、Loscalzo, J.(2015)。Harrison's Principles of Internal Medicine。McGraw-Hill。 | |
| |